NEW YORK (GenomeWeb News) – Genetic Technologies will distribute Rosetta Genomics' cancer diagnostic tests in Australia, New Zealand, and Singapore, under an exclusive agreement announced by Rosetta Genomics today.
GTG, a Melbourne-based genetic testing lab, will market the company's microRNA-based miRview tests in the three countries, Rosetta Genomics said.
The line of tests GTG will offer include the miRview mets, for diagnosing primary tumor site in metastatic cancer patients and patients with cancer of unknown primary origin; the miRview squamous, for differentiating squamous from non-squamous, non-small cell lung cancer; and the miRview meso, for differentiating mesothelioma from other cancers of the lung.
Rosetta Genomics Chief Commercialization Officer Ronen Tamir said in a statement that GTG is the firm's first distributor in the Pacific Rim region.
GTG CEO Paul MacLeman said that his company aims to "leverage in-house developed tests through partnering with third party developers of novel tests," in order to build a portfolio of genetic tests for the oncology market.